CoChat
Sign Up
Cited by 25Multiple Sclerosis Research StudiesGlaucoma and retinal disordersDrug-Induced Ocular Toxicity

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

The International Multiple Sclerosis Visual System Consortium : advancing visual system research in multiple sclerosis

Open access
Balcer, Laura J., Balk, Lisanne J., Brandt, Alexander U., Calabresi, Peter A., Martinez-Lapiscina, Elena H., Nolan, Rachel C., Paul, Friedemann, Petzold, Axel, Saidha, Shiv, on behalf of the IMSVISUAL Consortium·2018·Journal of Neuro-Ophthalmology
DOI 10.1097/wno.0000000000000732PMC PMC8898562
Open this paper in CoChat — free account

Abstract

Background: The International Multiple Sclerosis Visual System Consortium (IMSVISUAL) was formed in November 2014 with the primary goal of improving research, care, and education regarding the role of the visual system in multiple sclerosis (MS) and related disorders. Methods: In this review, we describe the formation, goals, activities, and structure of IMSVISUAL, as well as the relationship of IMSVISUAL with the Americas Committee for Treatment and Research in MS (ACTRIMS). Finally, we provide an overview of the work IMSVISUAL has completed to date, as well as an outline of research projects ongoing under the auspices of IMSVISUAL. Results: IMSVISUAL has 140 members worldwide and continues to grow. Through IMSVISUAL-related research, optical coherence tomography (OCT)-derived peripapillary retinal nerve fiber layer (pRNFL) thinning has been established as a predictor of future disability in MS. IMSVISUAL has also developed guidelines for reporting OCT studies in MS. Moreover, a systematic review performed by IMSVISUAL found that not only are pRNFL and ganglion cell + inner plexiform layer (GCIPL) thicknesses reduced in patients with MS (particularly in eyes with prior optic neuritis [ON]), but that inner nuclear layer measures may be higher among MS ON eyes, relative to healthy control eyes. Currently, there are several ongoing IMSVISUAL projects that will establish a role for visual outcomes in diagnosing MS and quantifying the effects of emerging therapies in clinical trials. Conclusions: The development of IMSVISUAL represents a major collaborative commitment to defining the role of visual outcomes in high-quality, large-scale studies that generate definitive and instructive findings in the field of MS. As a consortium, IMSVISUAL has completed several international collaborative projects, is actively engaged in numerous ongoing research studies, and is committed to expanding the role of vision research in MS and related disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/wno.0000000000000732

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 39

  1. Balcer, 2015, Vision and vision-related outcome measures in multiple sclerosis, Brain., 138, 11, 10.1093/brain/awu335 · DOI
  2. Petzold, 2010, Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis, Lancet Neurol., 9, 921, 10.1016/S1474-4422(10)70168-X · DOI
  3. Martinez-Lapiscina, 2016, Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study, Lancet Neurol., 15, 574, 10.1016/S1474-4422(16)00068-5 · DOI
  4. Kurtzke, 1983, Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology., 33, 1444, 10.1212/WNL.33.11.1444 · DOI · Paper page
  5. Rudick, 2009, Assessing disability progression with the multiple sclerosis functional composite, Mult Scler., 15, 984, 10.1177/1352458509106212 · DOI
  6. Wu, 2009, Signal strength is an important determinant of accuracy of nerve fiber layer thickness measurement by optical coherence tomography, J Glaucoma., 18, 213, 10.1097/IJG.0b013e31817eee20 · DOI
  7. Seigo, 2012, In vivo assessment of retinal neuronal layers in multiple sclerosis with manual and automated optical coherence tomography segmentation techniques, J Neurol., 259, 2119, 10.1007/s00415-012-6466-x · DOI
  8. Oberwahrenbrock, 2015, Reliability of intra-retinal layer thickness estimates, PLoS One., 10, e0137316, 10.1371/journal.pone.0137316 · DOI
  9. Schippling, 2015, Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria, Mult Scler., 21, 163, 10.1177/1352458514538110 · DOI
  10. Cruz-Herranz, 2016, The APOSTEL recommendations for reporting quantitative optical coherence tomography studies, Neurology., 86, 2303, 10.1212/WNL.0000000000002774 · DOI
  11. Petzold, 2017, Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis, Lancet Neurol., 16, 797, 10.1016/S1474-4422(17)30278-8 · DOI · Paper page
  12. Balk, 2014, A dam for retrograde axonal degeneration in multiple sclerosis?, J Neurol Neurosurg Psychiatry., 85, 782, 10.1136/jnnp-2013-306902 · DOI
  13. Balcer, 2006, Clinical practice. Optic neuritis, N Engl J Med., 354, 1273, 10.1056/NEJMcp053247 · DOI
  14. Toussaint, 1983, Clinicopathological study of the visual pathways, eyes, and cerebral hemispheres in 32 cases of disseminated sclerosis, J Clin Neuroophthalmol., 3, 211
  15. Ikuta, 1976, Distribution of plaques in seventy autopsy cases of multiple sclerosis in the United States, Neurology., 26, 26, 10.1212/WNL.26.6_Part_2.26 · DOI
  16. Thompson, 2018, Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria, Lancet Neurol., 17, 162, 10.1016/S1474-4422(17)30470-2 · DOI · Paper page
  17. Nolan, 2018, Optimal intereye difference thresholds in retinal nerve fiber layer thickness for predicting a unilateral optic nerve lesion in multiple sclerosis, J Neuroophthalmol., 38, 451, 10.1097/WNO.0000000000000629 · DOI
  18. Coric, 2017, Diagnostic accuracy of optical coherence tomography inter-eye percentage difference for optic neuritis in multiple sclerosis, Eur J Neurol., 24, 1479, 10.1111/ene.13443 · DOI
  19. Gelfand, 2012, Microcystic macular oedema in multiple sclerosis is associated with disease severity, Brain., 135, 1786, 10.1093/brain/aws098 · DOI
  20. Saidha, 2012, Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study, Lancet Neurol., 11, 963, 10.1016/S1474-4422(12)70213-2 · DOI
  21. Knier, 2016, Retinal inner nuclear layer volume reflects response to immunotherapy in multiple sclerosis, Brain., 139, 2855, 10.1093/brain/aww219 · DOI
  22. Tsakiri, 2012, Simvastatin improves final visual outcome in acute optic neuritis: a randomized study, Mult Scler., 18, 72, 10.1177/1352458511415452 · DOI
  23. Suhs, 2012, A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis, Ann Neurol., 72, 199, 10.1002/ana.23573 · DOI
  24. Esfahani, 2012, Memantine for axonal loss of optic neuritis, Graefes Arch Clin Exp Ophthalmol., 250, 863, 10.1007/s00417-011-1894-3 · DOI
  25. McKee, 2015, Amiloride Clinical Trial In Optic Neuritis (ACTION) protocol: a randomised, double blind, placebo controlled trial, BMJ Open., 5, e009200, 10.1136/bmjopen-2015-009200 · DOI
  26. Raftopoulos, 2016, Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial, Lancet Neurol., 15, 259, 10.1016/S1474-4422(16)00004-1 · DOI
  27. Cadavid, 2017, Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial, Lancet Neurol., 16, 189, 10.1016/S1474-4422(16)30377-5 · DOI
  28. Morrow, 2018, Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: a randomized clinical trial, JAMA Neurol., 75, 690, 10.1001/jamaneurol.2018.0024 · DOI
  29. Oberwahrenbrock, 2013, Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome, Mult Scler., 19, 1887, 10.1177/1352458513489757 · DOI
  30. Zimmermann, 2018, Association of retinal ganglion cell layer thickness with future disease activity in patients with clinically isolated syndrome, JAMA Neurol., 75, 1071, 10.1001/jamaneurol.2018.1011 · DOI
  31. Filippi, 2018, Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study, Lancet Neurol., 17, 133, 10.1016/S1474-4422(17)30469-6 · DOI · Paper page
  32. Krieger, 2016, The topographical model of multiple sclerosis: a dynamic visualization of disease course, Neurol Neuroimmunol Neuroinflamm., 3, e279, 10.1212/NXI.0000000000000279 · DOI
  33. Saidha, 2014, Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: yes, Mult Scler., 20, 1296, 10.1177/1352458514541509 · DOI
  34. Saidha, 2011, Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness, Mult Scler., 17, 1449, 10.1177/1352458511418630 · DOI
  35. Saidha, 2015, Optical coherence tomography reflects brain atrophy in multiple sclerosis: a four-year study, Ann Neurol., 78, 801, 10.1002/ana.24487 · DOI
  36. Button, 2017, Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: a retrospective study, Neurology., 88, 525, 10.1212/WNL.0000000000003582 · DOI
  37. Rocca, 2010, Thalamic damage and long-term progression of disability in multiple sclerosis, Radiology., 257, 463, 10.1148/radiol.10100326 · DOI
  38. Sotirchos, 2018, OCT is an alternative to MRI for monitoring MS - YES, Mult Scler., 24, 701, 10.1177/1352458517753722 · DOI
  39. Bermel, 2014, Outcome measures in multiple sclerosis, Mult Scler Int., 2014, 439375

Cited by

Sorted by citations

Metadata

Authors
Balcer, L. J., Balk, L. J., Brandt, A. U., Calabresi, P. A., Martinez-Lapiscina, E. H., Nolan, R. C., Paul, F., Petzold, A., Saidha, S., & on behalf of the IMSVISUAL Consortium
Affiliations
Johns Hopkins University (US)
Corresponding author
Saidha, Shiv
ORCID
Venue
Journal of Neuro-Ophthalmology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2018-12
Volume
38
Issue
4
Pages
494-501
ISSN
1070-8022 (ISSN-L)
DOI
10.1097/wno.0000000000000732
PMC
PMC8898562
OpenAlex
W2901826394
Cited by
25
References
3
Citations by year
2026: 2 · 2025: 5 · 2024: 4 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 2 · 2019: 4 · 2018: 1
FWCI
0.41
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuro-Ophthalmology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • National Institute for Health and Care Research
  • National Eye Institute (R01EY014993)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
  • Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
Keywords
multiple sclerosis, visual system, optical coherence tomography, disability prediction, ganglion cell-inner plexiform layer thickness, inner nuclear layer, optic neuritis, visual outcome, research consortium
MeSH terms
Eye Diseases, Humans, Multiple Sclerosis, Ophthalmology, Visual Acuity, Practice Guidelines as Topic, Disease Management, Biomedical Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review